The RET proto-oncogene in human cancers

被引:231
作者
Jhiang, SM
机构
[1] Ohio State Univ, Dept Cell Biol & Physiol, Columbus, OH 43210 USA
[2] Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA
关键词
RET; papillary thyroid carcinomas; MEN; 2; signal transduction;
D O I
10.1038/sj.onc.1203857
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The activation of the RET proto-oncogene contributes to the development of human cancers in two different ways. Somatic rearrangements of RET with a variety of activating genes, which contribute to unscheduled expression and constitutive dimerization of the chimeric RET/PTC oncoproteins in thyroid follicular cells, are frequently found in radiation-induced papillary thyroid carcinomas. Germ-line mutations, mainly point mutations, that lead to constitutive activation of RET tyrosine kinase activity are responsible for the development of the inherited cancer syndrome, multiple endocrine neoplasia type 2, There appears to be a correlation between specific types of RET mutation and clinical phenotypes of the cancers involved. The biological effects and the signaling pathways induced by different forms of RET activation have been investigated in a variety of cultured cells as well as in genetically engineered animal models. The identification of RET mutations in most MEN 2 families (95%) has translated into improved care for MEN 2 patients. However, further investigation of the signaling pathways contributing to tumorigenesis in relevant tissues will eventually help us to develop no, el strategies to prevent or to treat human papillary thyroid carcinomas, MEN 2 disease, as well as the sporadic cancers relevant to MEN 2 disease.
引用
收藏
页码:5590 / 5597
页数:8
相关论文
共 73 条
[1]   Multiple endocrine neoplasia type 2B mutation in human RET oncogene induces medullary thyroid carcinoma in transgenic mice [J].
Acton, DS ;
Velthuyzen, D ;
Lips, CJM ;
Höppener, JWM .
ONCOGENE, 2000, 19 (27) :3121-3125
[2]   GDNF family neurotrophic factor signaling: Four masters, one servant? [J].
Airaksinen, MS ;
Titievsky, A ;
Saarma, M .
MOLECULAR AND CELLULAR NEUROSCIENCE, 1999, 13 (05) :313-325
[3]   A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with Shc adaptor proteins [J].
Asai, N ;
Murakami, H ;
Iwashita, T ;
Takahashi, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (30) :17644-17649
[4]   Mechanism of Ret activation by a mutation at aspartic acid 631 identified in sporadic pheochromocytoma [J].
Asai, N ;
Iwashita, T ;
Murakami, H ;
Takanari, H ;
Ohmori, K ;
Ichihara, M ;
Takahashi, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 255 (03) :587-590
[5]   The GDNF family ligands and receptors - implications for neural development [J].
Baloh, RH ;
Enomoto, H ;
Johnson, EM ;
Milbrandt, J .
CURRENT OPINION IN NEUROBIOLOGY, 2000, 10 (01) :103-110
[6]   A RET double mutation in the germline of a kindred with FMTC [J].
Bartsch, DK ;
Hasse, C ;
Schug, C ;
Barth, P ;
Rothmund, M ;
Höppner, W .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2000, 108 (02) :128-132
[7]   The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck [J].
Bocciardi, R ;
Mograbi, B ;
Pasini, B ;
Borrello, MG ;
Pierotti, MA ;
Bourget, I ;
Fischer, S ;
Romeo, G ;
Rossi, B .
ONCOGENE, 1997, 15 (19) :2257-2265
[8]  
BOND JA, 1994, ONCOGENE, V9, P281
[9]  
Borrello MG, 1996, MOL CELL BIOL, V16, P2151
[10]   High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation [J].
Bounacer, A ;
Wicker, R ;
Caillou, B ;
Cailleux, AF ;
Sarasin, A ;
Schlumberger, M ;
Suarez, HG .
ONCOGENE, 1997, 15 (11) :1263-1273